ASX - By Stock
|
EZZ |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Eqz
|
48 |
14K |
1 |
05/08/24 |
05/08/24 |
ASX - By Stock
|
48
|
14K
|
1
|
|
ASX - By Stock
|
EZZ |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Eqz
|
48 |
14K |
1 |
03/08/24 |
03/08/24 |
ASX - By Stock
|
48
|
14K
|
1
|
|
ASX - By Stock
|
EYE |
Re:
CMS Proposes Major Increase in Reimbursement for Canaloplasty
|
|
Eqz
|
507 |
119K |
18 |
03/08/24 |
03/08/24 |
ASX - By Stock
|
507
|
119K
|
18
|
|
ASX - By Stock
|
EYE |
Re:
CMS Proposes Major Increase in Reimbursement for Canaloplasty
|
|
Eqz
|
507 |
119K |
4 |
02/08/24 |
02/08/24 |
ASX - By Stock
|
507
|
119K
|
4
|
|
ASX - By Stock
|
EYE |
Re:
CMS Proposes Major Increase in Reimbursement for Canaloplasty
|
|
Eqz
|
507 |
119K |
13 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
507
|
119K
|
13
|
|
ASX - By Stock
|
TRP |
Re:
Ann: Company Update - Presentation
|
|
Eqz
|
17 |
4.4K |
5 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
17
|
4.4K
|
5
|
|
ASX - By Stock
|
IMC |
Re:
Clinical Programs
|
|
Eqz
|
10 |
3.8K |
4 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
10
|
3.8K
|
4
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Eqz
|
97 |
37K |
17 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
97
|
37K
|
17
|
|
ASX - By Stock
|
OSX |
Re:
Ann: Activities Update Qtr Ending June 2024 and Appendix 4C
|
|
Eqz
|
30 |
13K |
1 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
30
|
13K
|
1
|
|
ASX - By Stock
|
EZZ |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Eqz
|
48 |
14K |
3 |
30/07/24 |
30/07/24 |
ASX - By Stock
|
48
|
14K
|
3
|
|
ASX - By Stock
|
EZZ |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Eqz
|
48 |
14K |
5 |
29/07/24 |
29/07/24 |
ASX - By Stock
|
48
|
14K
|
5
|
|
ASX - By Stock
|
IMC |
Clinical Programs
|
|
Eqz
|
10 |
3.8K |
1 |
27/07/24 |
27/07/24 |
ASX - By Stock
|
10
|
3.8K
|
1
|
|
ASX - By Stock
|
IMC |
Re:
Ann: Immuron CEO to present at Emerging Growth Conference
|
|
Eqz
|
14 |
3.9K |
1 |
26/07/24 |
26/07/24 |
ASX - By Stock
|
14
|
3.9K
|
1
|
|
ASX - By Stock
|
TRP |
Re:
Ann: TGA approval granted for Tissue Repair TR Pro
|
|
Eqz
|
25 |
6.5K |
1 |
26/07/24 |
26/07/24 |
ASX - By Stock
|
25
|
6.5K
|
1
|
|
ASX - By Stock
|
EYE |
Re:
CMS Proposes Major Increase in Reimbursement for Canaloplasty
|
|
Eqz
|
507 |
119K |
7 |
25/07/24 |
25/07/24 |
ASX - By Stock
|
507
|
119K
|
7
|
|
ASX - By Stock
|
TRP |
Re:
Ann: TGA approval granted for Tissue Repair TR Pro
|
|
Eqz
|
25 |
6.5K |
1 |
25/07/24 |
25/07/24 |
ASX - By Stock
|
25
|
6.5K
|
1
|
|
ASX - By Stock
|
TRP |
Re:
Ann: TGA approval granted for Tissue Repair TR Pro
|
|
Eqz
|
25 |
6.5K |
3 |
25/07/24 |
25/07/24 |
ASX - By Stock
|
25
|
6.5K
|
3
|
|
ASX - By Stock
|
TRP |
Re:
Ann: TGA approval granted for Tissue Repair TR Pro
|
|
Eqz
|
25 |
6.5K |
1 |
25/07/24 |
25/07/24 |
ASX - By Stock
|
25
|
6.5K
|
1
|
|
ASX - By Stock
|
TRP |
Re:
Ann: TGA approval granted for Tissue Repair TR Pro
|
|
Eqz
|
25 |
6.5K |
7 |
25/07/24 |
25/07/24 |
ASX - By Stock
|
25
|
6.5K
|
7
|
|
ASX - By Stock
|
TRP |
Re:
Ann: TGA approval granted for Tissue Repair TR Pro
|
|
Eqz
|
25 |
6.5K |
6 |
25/07/24 |
25/07/24 |
ASX - By Stock
|
25
|
6.5K
|
6
|
|
ASX - By Stock
|
TRP |
Re:
Ann: TGA approval granted for Tissue Repair TR Pro
|
|
Eqz
|
25 |
6.5K |
4 |
25/07/24 |
25/07/24 |
ASX - By Stock
|
25
|
6.5K
|
4
|
|
ASX - By Stock
|
TRP |
Re:
Ann: TGA approval granted for Tissue Repair TR Pro
|
|
Eqz
|
25 |
6.5K |
4 |
25/07/24 |
25/07/24 |
ASX - By Stock
|
25
|
6.5K
|
4
|
|
ASX - By Stock
|
EZZ |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Eqz
|
48 |
14K |
2 |
24/07/24 |
24/07/24 |
ASX - By Stock
|
48
|
14K
|
2
|
|
ASX - By Stock
|
SVL |
Re:
Ann: SVL Secures A$30.2 Million Convertible Debenture Funding
|
|
Eqz
|
62 |
34K |
1 |
24/07/24 |
24/07/24 |
ASX - By Stock
|
62
|
34K
|
1
|
|
ASX - By Stock
|
SVL |
Re:
Ann: SVL Secures A$30.2 Million Convertible Debenture Funding
|
|
Eqz
|
62 |
34K |
0 |
24/07/24 |
24/07/24 |
ASX - By Stock
|
62
|
34K
|
0
|
|
ASX - By Stock
|
SVL |
Re:
Ann: Bowdens Silver Successfully Defends Judicial Proceedings
|
|
Eqz
|
105 |
63K |
0 |
24/07/24 |
24/07/24 |
ASX - By Stock
|
105
|
63K
|
0
|
|
ASX - By Stock
|
SVL |
Re:
Ann: Bowdens Silver Successfully Defends Judicial Proceedings
|
|
Eqz
|
105 |
63K |
1 |
23/07/24 |
23/07/24 |
ASX - By Stock
|
105
|
63K
|
1
|
|
ASX - By Stock
|
EZZ |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Eqz
|
48 |
14K |
0 |
23/07/24 |
23/07/24 |
ASX - By Stock
|
48
|
14K
|
0
|
|
ASX - By Stock
|
EZZ |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Eqz
|
48 |
14K |
0 |
23/07/24 |
23/07/24 |
ASX - By Stock
|
48
|
14K
|
0
|
|
ASX - By Stock
|
FGR |
Re:
Ann: Pivotal role secured in $3.72m project
|
|
Eqz
|
3 |
2.2K |
3 |
22/07/24 |
22/07/24 |
ASX - By Stock
|
3
|
2.2K
|
3
|
|
ASX - By Stock
|
EYE |
Re:
CMS Proposes Major Increase in Reimbursement for Canaloplasty
|
|
Eqz
|
507 |
119K |
1 |
20/07/24 |
20/07/24 |
ASX - By Stock
|
507
|
119K
|
1
|
|
ASX - By Stock
|
EYE |
Re:
CMS Proposes Major Increase in Reimbursement for Canaloplasty
|
|
Eqz
|
507 |
119K |
1 |
19/07/24 |
19/07/24 |
ASX - By Stock
|
507
|
119K
|
1
|
|
ASX - By Stock
|
EYE |
Re:
CMS Proposes Major Increase in Reimbursement for Canaloplasty
|
|
Eqz
|
507 |
119K |
5 |
19/07/24 |
19/07/24 |
ASX - By Stock
|
507
|
119K
|
5
|
|
ASX - By Stock
|
SVL |
Re:
Ann: SVL Secures A$30.2 Million Convertible Debenture Funding
|
|
Eqz
|
62 |
34K |
5 |
18/07/24 |
18/07/24 |
ASX - By Stock
|
62
|
34K
|
5
|
|
ASX - By Stock
|
IMC |
Re:
Ann: Immuron CEO to present at Emerging Growth Conference
|
|
Eqz
|
14 |
3.9K |
0 |
18/07/24 |
18/07/24 |
ASX - By Stock
|
14
|
3.9K
|
0
|
|
ASX - By Stock
|
SVL |
Re:
Ann: SVL Secures A$30.2 Million Convertible Debenture Funding
|
|
Eqz
|
62 |
34K |
17 |
18/07/24 |
18/07/24 |
ASX - By Stock
|
62
|
34K
|
17
|
|
ASX - By Stock
|
OSX |
Re:
Ann: Osteopore strikes Exclusive Distribution with Zimmer Biomet
|
|
Eqz
|
66 |
23K |
8 |
17/07/24 |
17/07/24 |
ASX - By Stock
|
66
|
23K
|
8
|
|
ASX - By Stock
|
OSX |
Re:
Ann: Osteopore strikes Exclusive Distribution with Zimmer Biomet
|
|
Eqz
|
66 |
23K |
4 |
16/07/24 |
16/07/24 |
ASX - By Stock
|
66
|
23K
|
4
|
|
ASX - By Stock
|
OSX |
Re:
Ann: Osteopore strikes Exclusive Distribution with Zimmer Biomet
|
|
Eqz
|
66 |
23K |
4 |
16/07/24 |
16/07/24 |
ASX - By Stock
|
66
|
23K
|
4
|
|
ASX - By Stock
|
OSX |
Re:
Ann: Osteopore strikes Exclusive Distribution with Zimmer Biomet
|
|
Eqz
|
66 |
23K |
6 |
16/07/24 |
16/07/24 |
ASX - By Stock
|
66
|
23K
|
6
|
|
ASX - By Stock
|
OSX |
Re:
Ann: Osteopore strikes Exclusive Distribution with Zimmer Biomet
|
|
Eqz
|
66 |
23K |
8 |
16/07/24 |
16/07/24 |
ASX - By Stock
|
66
|
23K
|
8
|
|
ASX - By Stock
|
OSX |
Re:
Ann: Osteopore strikes Exclusive Distribution with Zimmer Biomet
|
|
Eqz
|
66 |
23K |
1 |
16/07/24 |
16/07/24 |
ASX - By Stock
|
66
|
23K
|
1
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Imugene Corporate Presentation
|
|
Eqz
|
159 |
83K |
137 |
15/07/24 |
15/07/24 |
ASX - By Stock
|
159
|
83K
|
137
|
|
ASX - By Stock
|
IMC |
Re:
Ann: Immuron Travelan record sales globally, Australia and USA
|
|
Eqz
|
23 |
7.4K |
5 |
15/07/24 |
15/07/24 |
ASX - By Stock
|
23
|
7.4K
|
5
|
|
ASX - By Stock
|
SNS |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Eqz
|
5 |
3.7K |
4 |
15/07/24 |
15/07/24 |
ASX - By Stock
|
5
|
3.7K
|
4
|
|
ASX - By Stock
|
IMC |
Re:
Ann: Immuron CEO Steven Lydeamore presentation to Sharewise
|
|
Eqz
|
24 |
5.8K |
3 |
12/07/24 |
12/07/24 |
ASX - By Stock
|
24
|
5.8K
|
3
|
|
ASX - By Stock
|
IMC |
Re:
Ann: Immuron CEO Steven Lydeamore presentation to Sharewise
|
|
Eqz
|
24 |
5.8K |
3 |
12/07/24 |
12/07/24 |
ASX - By Stock
|
24
|
5.8K
|
3
|
|
Charts
|
SVL |
Re:
SVL chart
|
|
Eqz
|
3.0K |
1.4M |
3 |
12/07/24 |
12/07/24 |
Charts
|
3.0K
|
1.4M
|
3
|
|
Charts
|
SVL |
Re:
SVL chart
|
|
Eqz
|
3.0K |
1.4M |
1 |
12/07/24 |
12/07/24 |
Charts
|
3.0K
|
1.4M
|
1
|
|
ASX - By Stock
|
IMC |
Re:
Ann: Immuron CEO Steven Lydeamore presentation to Sharewise
|
|
Eqz
|
24 |
5.8K |
1 |
12/07/24 |
12/07/24 |
ASX - By Stock
|
24
|
5.8K
|
1
|
|